• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CSCs生物标志物CD133在非小细胞肺癌中的预后价值：一项荟萃分析。

The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.

作者信息

Chen Engeng, Zeng Zhiru, Bai Bingjun, Zhu Jing, Song Zhangfa

机构信息

Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, P.R. China.

Key Laboratory of Biotherapy of Zhejiang Province, 310016, P.R. China.

出版信息

Oncotarget. 2016 Aug 30;7(35):56526-56539. doi: 10.18632/oncotarget.10964.

DOI:10.18632/oncotarget.10964
PMID:27489355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5302932/
Abstract

The prognostic value of cancer stem cells (CSCs) marker CD133 in non-small-cell lung cancer (NSCLC) remains controversial. We performed this meta-analysis of 32 eligible studies to clarify the prognostic value of CD133 and provide evidence for CSCs hypothesis. We calculated pooled hazard ratio (HR) for survival outcomes and pooled odds ratio (OR) for clinical parameters associated with CD133 in total 3595 NSCLC patients by STATA. Our results showed that NSCLC patients with higher CD133 expression had shorter overall survival time only in Asian patients (HR = 3.80, 95% CI: 3.12-4.04, p < 0.001; I2 = 32%) but not in Caucasian patients (HR = 1.15, 95% CI: 0.88-1.52, p = 0.307; I2 = 0%), suggesting that differential prognostic value of CD133 in distinct ethnic group. We speculated that the intrinsic EGFR gene status of CSCs might be responsible for this racial difference. Additionally, we found that higher expression of CD133 was associated with poor differentiation (OR = 2.03, 95% CI: 1.32-3.14, p = 0.001) and lymph node metastasis (OR = 2.39, 95% CI: 1.62-3.52, p < 0.001) but there was no significant difference of CD133 expression between adenocarcinoma and squamous carcinoma (OR = 1.13, 95% CI: 0.93-1.38, p = 0.3) in NSCLC patients. These results may provide a new therapeutic perspective on the treatment of NSCLC patients according to the expression of CD133 in distinct ethnic group.

摘要

癌症干细胞（CSCs）标志物CD133在非小细胞肺癌（NSCLC）中的预后价值仍存在争议。我们对32项符合条件的研究进行了这项荟萃分析，以阐明CD133的预后价值，并为癌症干细胞假说提供证据。我们通过STATA计算了3595例NSCLC患者生存结局的合并风险比（HR）以及与CD133相关的临床参数的合并比值比（OR）。我们的结果显示，仅在亚洲患者中，CD133表达较高的NSCLC患者总生存时间较短（HR = 3.80，95%CI：3.12 - 4.04，p < 0.001；I2 = 32%），而在白种人患者中并非如此（HR = 1.15，95%CI：0.88 - 1.52，p = 0.307；I2 = 0%），这表明CD133在不同种族群体中的预后价值存在差异。我们推测癌症干细胞的内在表皮生长因子受体（EGFR）基因状态可能是造成这种种族差异的原因。此外，我们发现CD133表达较高与低分化（OR = 2.03，95%CI：1.32 - 3.14，p = 0.001）和淋巴结转移（OR = 2.39，95%CI：1.62 - 3.52，p < 0.001）相关，但在NSCLC患者中，腺癌和鳞癌之间CD133表达无显著差异（OR = 1.13，95%CI：0.93 - 1.38，p = 0.3）。这些结果可能会根据不同种族群体中CD133的表达情况为NSCLC患者的治疗提供新的治疗视角。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/0d8767eb0557/oncotarget-07-56526-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/16ddbb417327/oncotarget-07-56526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/8caa36862c19/oncotarget-07-56526-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/9d839886792f/oncotarget-07-56526-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/adbb8cc8203f/oncotarget-07-56526-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/ee82e4aeb827/oncotarget-07-56526-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/0d8767eb0557/oncotarget-07-56526-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/16ddbb417327/oncotarget-07-56526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/8caa36862c19/oncotarget-07-56526-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/9d839886792f/oncotarget-07-56526-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/adbb8cc8203f/oncotarget-07-56526-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/ee82e4aeb827/oncotarget-07-56526-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/5302932/0d8767eb0557/oncotarget-07-56526-g006.jpg

相似文献

1
The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.CSCs生物标志物CD133在非小细胞肺癌中的预后价值：一项荟萃分析。
Oncotarget. 2016 Aug 30;7(35):56526-56539. doi: 10.18632/oncotarget.10964.
2
Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.CD133表达是否是非小细胞肺癌的预后生物标志物？一项系统评价和荟萃分析。
PLoS One. 2014 Jun 18;9(6):e100168. doi: 10.1371/journal.pone.0100168. eCollection 2014.
3
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.CD133和癌胚抗原在Ib-IIIA期非小细胞肺癌中的预测和预后作用
Int J Clin Exp Pathol. 2015 May 1;8(5):5509-18. eCollection 2015.
4
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.CD133 是耐药表型的标志物，但不能代表非小细胞肺癌患者生存的预后标志物。
Int J Cancer. 2010 Feb 15;126(4):950-8. doi: 10.1002/ijc.24822.
5
A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.一项荟萃分析揭示了程序性死亡配体-1在亚洲非小细胞肺癌患者中的预后作用。
J Huazhong Univ Sci Technolog Med Sci. 2016 Jun;36(3):313-320. doi: 10.1007/s11596-016-1585-8. Epub 2016 Jul 5.
6
The roles of CD133 expression in the patients with non-small cell lung cancer.CD133 表达在非小细胞肺癌患者中的作用。
Cancer Biomark. 2018;22(3):385-394. doi: 10.3233/CBM-170835.
7
The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.CD133表达在非小细胞肺癌中的预后价值：一项荟萃分析。
Tumour Biol. 2014 Oct;35(10):9769-75. doi: 10.1007/s13277-014-2270-9. Epub 2014 Jun 29.
8
The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.CD133 表达在肺癌患者发生发展和预后中的作用。
Mol Med Rep. 2013 Nov;8(5):1511-8. doi: 10.3892/mmr.2013.1667. Epub 2013 Sep 4.
9
Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma.癌症干细胞标志物 CD47 和 CD133 在食管鳞癌中的联合预后价值。
Cancer Med. 2019 Mar;8(3):1315-1325. doi: 10.1002/cam4.1894. Epub 2019 Feb 11.
10
Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.S100A4 表达在非小细胞肺癌中的临床病理和预后价值：一项荟萃分析。
Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20201710.

引用本文的文献

1
The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection.糖基化对CD133功能活性及其免疫检测准确性的影响
Biology (Basel). 2024 Jun 18;13(6):449. doi: 10.3390/biology13060449.
2
Cancer Stem Cells from Definition to Detection and Targeted Drugs.从定义到检测与靶向药物的癌症干细胞
Int J Mol Sci. 2024 Mar 31;25(7):3903. doi: 10.3390/ijms25073903.
3
Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons.CD133 能否作为肿瘤学中的预后生物标志物：利弊分析。

本文引用的文献

1
The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections.美国癌症协会挑战目标：1990 年至 2015 年美国癌症死亡率降低 50%：结果与反思。
CA Cancer J Clin. 2016 Sep;66(5):359-69. doi: 10.3322/caac.21348. Epub 2016 May 13.
2
Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.Oct4在吉非替尼耐药的肺癌干细胞维持中起着关键作用。
Biochem Biophys Res Commun. 2016 Apr 22;473(1):125-132. doi: 10.1016/j.bbrc.2016.03.064. Epub 2016 Mar 17.
3
Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
Int J Mol Sci. 2023 Dec 12;24(24):17398. doi: 10.3390/ijms242417398.
4
Novel piRNA MW557525 regulates the growth of Piwil2-iCSCs and maintains their stem cell pluripotency.新型 piRNA MW557525 调控 Piwil2-iCSCs 的生长并维持其干细胞多能性。
Mol Biol Rep. 2022 Jul;49(7):6957-6969. doi: 10.1007/s11033-022-07443-9. Epub 2022 Apr 11.
5
Integrin-α7 expression positively correlates with CD44 and CD133 expressions, and its high expression associates with advanced tumor features as well as poor survivals in non-small cell lung cancer patients.整合素α7的表达与CD44和CD133的表达呈正相关，其高表达与非小细胞肺癌患者的肿瘤进展特征以及较差的生存率相关。
Transl Cancer Res. 2019 Sep;8(5):1806-1816. doi: 10.21037/tcr.2019.08.31.
6
CD2 T-helper 17-like cells differentiated from a CD133 subpopulation of non-small cell lung carcinoma cells promote the growth of lung carcinoma.从非小细胞肺癌细胞的CD133亚群分化而来的CD2 T辅助17样细胞促进肺癌生长。
Ann Transl Med. 2021 Apr;9(8):687. doi: 10.21037/atm-21-980.
7
Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.癌症干细胞的起源和生物标志物：靶向个体化治疗的新视角。
Front Immunol. 2020 Aug 7;11:1280. doi: 10.3389/fimmu.2020.01280. eCollection 2020.
8
Expression of ALDH1A1 and CD133 is associated with the prognosis and effect of different chemotherapeutic regimens in gastric cancer.ALDH1A1和CD133的表达与胃癌不同化疗方案的预后及疗效相关。
Oncol Lett. 2019 Nov;18(5):4573-4582. doi: 10.3892/ol.2019.10798. Epub 2019 Sep 4.
9
Targeting of CD133+ Cancer Stem Cells by Mesenchymal Stem Cell Expressing TRAIL Reveals a Prospective Role of Apoptotic Gene Regulation in Non-Small Cell Lung Cancer.表达TRAIL的间充质干细胞靶向CD133 +癌症干细胞揭示了凋亡基因调控在非小细胞肺癌中的潜在作用。
Cancers (Basel). 2019 Aug 28;11(9):1261. doi: 10.3390/cancers11091261.
10
Prognostic Value of CD133 and SOX2 in Advanced Cancer.CD133和SOX2在晚期癌症中的预后价值
J Oncol. 2019 Jan 1;2019:3905817. doi: 10.1155/2019/3905817. eCollection 2019.
肝癌干细胞标志物颗粒体蛋白-上皮素前体和β-连环蛋白的表达与肝细胞癌复发相关。
Oncotarget. 2016 Apr 19;7(16):21644-57. doi: 10.18632/oncotarget.7803.
4
CD133 promotes gallbladder carcinoma cell migration through activating Akt phosphorylation.CD133通过激活Akt磷酸化促进胆囊癌细胞迁移。
Oncotarget. 2016 Apr 5;7(14):17751-9. doi: 10.18632/oncotarget.7474.
5
mDia1 regulates breast cancer invasion by controlling membrane type 1-matrix metalloproteinase localization.mDia1通过控制膜型1基质金属蛋白酶的定位来调节乳腺癌侵袭。
Oncotarget. 2016 Apr 5;7(14):17829-43. doi: 10.18632/oncotarget.7429.
6
CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis.CD133表达可能作为结直肠癌的预后指标、优化治疗的工具及癌症干细胞假说的支持证据：一项荟萃分析。
Oncotarget. 2016 Mar 1;7(9):10023-36. doi: 10.18632/oncotarget.7054.
7
Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer.胃癌中干细胞样细胞的鉴定及候选干细胞标志物的临床意义
Oncotarget. 2016 Mar 1;7(9):9815-31. doi: 10.18632/oncotarget.6890.
8
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
9
[Expression and pathological mechanism of MMP-9 and HIF-2α in CD133(+) lung cancer stem cells].MMP-9和HIF-2α在CD133(+)肺癌干细胞中的表达及病理机制
Zhonghua Yi Xue Za Zhi. 2015 Aug 25;95(32):2607-11.
10
Ethnicity affects and gene alterations of lung adenocarcinoma.种族影响肺腺癌的基因改变。
Oncol Lett. 2015 Sep;10(3):1775-1782. doi: 10.3892/ol.2015.3414. Epub 2015 Jun 23.